PHAT vs. ZYME, CALT, MLYS, GHRS, PHAR, ABUS, ANAB, PHVS, ORIC, and SVRA
Should you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Mineralys Therapeutics (MLYS), GH Research (GHRS), Pharming Group (PHAR), Arbutus Biopharma (ABUS), AnaptysBio (ANAB), Pharvaris (PHVS), ORIC Pharmaceuticals (ORIC), and Savara (SVRA). These companies are all part of the "pharmaceutical preparations" industry.
Zymeworks (NYSE:ZYME) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment.
In the previous week, Phathom Pharmaceuticals had 6 more articles in the media than Zymeworks. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.57 beat Phathom Pharmaceuticals' score of -0.66 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.
Phathom Pharmaceuticals has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -249.63%. Zymeworks' return on equity of 0.00% beat Phathom Pharmaceuticals' return on equity.
Zymeworks has higher revenue and earnings than Phathom Pharmaceuticals. Zymeworks is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Zymeworks presently has a consensus price target of $12.67, indicating a potential upside of 49.37%. Phathom Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 118.25%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Zymeworks.
Zymeworks received 216 more outperform votes than Phathom Pharmaceuticals when rated by MarketBeat users. Likewise, 68.59% of users gave Zymeworks an outperform vote while only 67.96% of users gave Phathom Pharmaceuticals an outperform vote.
92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 1.2% of Zymeworks shares are owned by company insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Zymeworks has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.
Summary
Phathom Pharmaceuticals beats Zymeworks on 11 of the 18 factors compared between the two stocks.
Get Phathom Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phathom Pharmaceuticals Competitors List
Related Companies and Tools
